Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals is favorably positioned because its lead asset palazestrant addresses a large endocrine-sensitive breast cancer population that remains underserved, including ESR1 wild-type patients whom approved 2L+ oral SERDs do not reach. The strong Phase 1b/2 data at ESMO 2025, with mPFS of 15.5 months overall and 9.2 months in ESR1wt patients, support a differentiated mechanism, while Inluriyo’s $75M in 2Q26 worldwide sales and $110M YTD validate commercial demand for oral SERD therapy. Its pipeline depth further strengthens the outlook, as OP-3136 showed 68% tumor shrinkage in 19 evaluable patients with no DLTs or Grade 4/5 TRAEs, and multiple partnerships and combination studies could expand the franchise across breast cancer and beyond.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products, so its valuation remains highly dependent on unproven palazestrant and OP-3136 pipeline execution. The 2Q26 results underscore rising cash burn, with total operating expenses of $67.2M and EPS of ($0.61), driven by costly Phase 3 OPERA-01 and OPERA-02 work and the Phase 1 OP-3136 trial, while cash and equivalents of $461.1M only support operations into 2028. A delay in topline OPERA-01 data pushes commercialization to 2028, and the outlook is further weakened by the need for substantial additional financing, competitive pressures, and meaningful clinical, safety, and regulatory risks.